New Research Says

How many times when you are talking to your doctor have you heard them say'new research says...'or'recent studies have shown....'? I get it all the time. And I am not sure I like it. Or how it makes me feel...I realize being a doctor or other medical professional takes a lot of work and study just to get there and then they need to constantly work at staying up to date so of course they are reading research and following studies. But when they shove it in my face by saying that the new research told them this, I feel like they aren't practicing medicine but reading research.I realize a lot of new information comes out for doctors through medical research - that's how they learn more. But I realize research isn't everything. I think of as'flat'. A research project is done with a goal to prove or disprove something and it is done with a certain pool of people that meet specific criteria. I have never been eligible for a single research project (a/k/a clinical trial) because my medical background is too complicated. It doesn't reflect the real world where people may have multiple ailments, allergies, genetic make up, etc. Doesn't all medical research always end with'more research is needed'?A medical professional needs to keep up on the latest research but they also need to learn how it works in the real world with real patients. We are people with real ailments. I don't want statistics or research quoted to me. I want real medical advice which incorporates the research and my m...
Source: Caroline's Breast Cancer Blog - Category: Cancer & Oncology Tags: being a patient clinical trials medical research uncertainty with doctors Source Type: blogs

Related Links:

This study aim to investigate the association of breast cancer risk and prognostic factors with single nucleotide variants of the BRCA1, BRCA2, DAPK1, MMP9, TOX3, and TP53 genes in Jordanian women. Blood samples were collected from 230 Jordanian breast cancer patients for use in DNA extraction followed by genotyping and subsequent statistical analysis. We found that two single nucleotide variants (SNVs) of the BRCA2 gene, namely rs1799944 and rs766173, were significantly associated with breastfeeding status. Likewise, the rs11141901 and rs1041326 SNVs of the DAPK1 gene were linked with co-morbidity (p-value = 0.002) and fa...
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research
CONCLUSION: IV NEPA was highly effective and safe with no associated hypersensitivity and injection-site reactions in patients receiving AC. IMPLICATIONS FOR PRACTICE: As a combination of a neurokinin-1 (NK1) receptor antagonist (RA) and 5-HT3RA, NEPA offers 5-day chemotherapy-induced nausea and vomiting prevention with a single dose and an opportunity to improve adherence to antiemetic guidelines. In this randomized multinational phase IIIb study, intravenous (IV) NEPA (fosnetupitant/palonosetron) was safe and highly effective in patients receiving multiple cycles of anthracycline-cyclophosphamide (AC)-based chemothe...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research
Trastuzumab is a humanized mouse IgG1 mAb with selective affinity for the human EGF2 protein, HER-2, approved for the treatment of metastatic breast cancer. Rates of hypersensitivity reaction range from 0.6 to 5%.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Source Type: research
We present a case of acute urticaria and angioedema after radiotherapy.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Source Type: research
The agency proposed that surgeons discuss the risks with patients and that manufacturers print bold warnings on the device packaging.
Source: NYT Health - Category: Consumer Health News Authors: Tags: your-feed-science Implants Breasts Medical Devices Breast Cancer Plastic Surgery Labeling and Labels (Product) Surgery and Surgeons Silicone Autoimmune Diseases Allergan Inc Food and Drug Administration Source Type: news
AbstractBackgroundCLEOPATRA study demonstrated the efficacy and safety of pertuzumab (P) + trastuzumab (T) + docetaxel (D) but efficacy results of Japanese subgroup weren ’t consistent with the whole study results. A phase IV, multicenter, prospective, COMACHI study was conducted in Japan to re-confirm the efficacy and safety of P+T+D demonstrated in the CLEOPATRA study.MethodsPatients (pts) with HER2-positive breast cancer who were diagnosed as Stage IV or recurred more than a year after (neo)adjuvant taxane chemotherapy completion were enrolled. Pts were administered study drugs intravenously every 3 weeks. Discont...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
The awards honor scientists who made'monumental'achievements in discovering B and T cells and the first targeted therapy for breast cancer.Medscape Medical News
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Hematology-Oncology News Alert Source Type: news
Roche's Tecentriq (atezolizumab) has won European approval for use against a tough-to-treat breast cancer, helping the Swiss drugmaker to widen use of an immunotherapy that has so far been eclipsed in revenue terms by more-established rival medicines.Reuters Health Information
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news
FINDINGSCancer that has spread to the central nervous system is notoriously difficult to treat. Now, UCLA researchers have developed a drug delivery system that breaks through the blood-brain barrier in order to reach and treat cancer that has spread to the central nervous system.In research conducted in mice, a single dose of cancer drugs in a nanoscale capsule developed by the scientists eliminated all B-cell lymphoma that had metastasized to the animals ’ central nervous system.BACKGROUNDAbout 15% to 40% of all cancers spread to the nervous system, but there are few treatment options and they only work in a small ...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
FDA has finally drawn a line in the sand on an issue that has plagued the breast implant industry for years. On Wednesday the U.S. regulatory agency called on Allergan to take specific models of its textured breast implants off the market due to the risk of a rare type of cancer. "To protect individuals from the increased risk of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) associated with Allergan Biocell textured breast implants, [FDA] requested that Allergan recall its Biocell textured breast implants and tissue expanders," the agency said in a safety communicatio...
Source: MDDI - Category: Medical Devices Authors: Tags: Regulatory and Compliance Source Type: news
More News: Allergy | Allergy & Immunology | Blogging | Breast Cancer | Cancer | Cancer & Oncology | Clinical Trials | Genetics | Learning | Research | Statistics | Study | Universities & Medical Training